Accelerated approval enables investigational drugs to reach the US market on the basis of their demonstrated effects in unvalidated surrogate measures, only reasonably likely to predict clinical response. To fulfil the social compromise, regulators should ensure that confirmatory trials testing clinically meaningful end points are already underway at the time of approval.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
The European Journal of Health Economics Open Access 14 November 2023
-
Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement
British Journal of Cancer Open Access 06 January 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Beaver, J. A. et al. A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review. JAMA Oncol. 4, 849–856 (2018).
Kesselheim, A. S. et al. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study. BMJ 351, h4633 (2015).
Naci, H., Smalley, K. R. & Kesselheim, A. S. Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US Food and Drug Administration. JAMA 318, 626–636 (2017).
Zettler, M. & Nabhan, C. Fulfillment of postmarketing requirements to the FDA for therapies granted oncology indications between 2011 and 2016. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2018.0610 (2018).
FDA. Postmarket requirements and commitments database. FDA https://www.accessdata.fda.gov/scripts/cder/pmc/index.cfm (2018).
Meadows, M. Promoting safe and effective drugs for 100 years. FDA https://www.fda.gov/downloads/AboutFDA/WhatWeDo/History/FOrgsHistory/CDER/UCM586463.pdf (2006).
Gellad, W. F. & Kesselheim, A. S. Accelerated approval and expensive drugs — a challenging combination. N. Engl. J. Med. 376, 2001–2004 (2017).
Vivot, A. et al. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015. Ann. Oncol. 28, 1111–1116 (2017).
Acknowledgements
The work of A.S.K. and B.G. on this project was funded by the Laura and John Arnold Foundation. A.S.K. receives grant support from the Engelberg Foundation and the Harvard Program in Therapeutic Science. These funders had no role in any aspect related to the publication of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.S.K. has received unrelated research funding from the FDA Division of Health Communication and Office of Generic Drugs (2013–2016). B.G. declares no competing interests.
Rights and permissions
About this article
Cite this article
Gyawali, B., Kesselheim, A.S. Reinforcing the social compromise of accelerated approval. Nat Rev Clin Oncol 15, 596–597 (2018). https://doi.org/10.1038/s41571-018-0066-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-018-0066-3
This article is cited by
-
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
The European Journal of Health Economics (2023)
-
Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement
British Journal of Cancer (2020)
-
ANNOUNCE prompts questions over the Accelerated Approval process
Nature Reviews Clinical Oncology (2019)
-
A reality check of the accelerated approval of immune-checkpoint inhibitors
Nature Reviews Clinical Oncology (2019)